Andrew Pierce - Stryker Group Neurotechnology
| SYK Stock | EUR 348.50 4.30 1.25% |
Insider
Andrew Pierce is Group Neurotechnology of Stryker
| Age | 49 |
| Phone | 269 385 2600 |
| Web | https://www.stryker.com |
Stryker Management Efficiency
The company has return on total asset (ROA) of 0.0618 % which means that it generated a profit of $0.0618 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1498 %, meaning that it generated $0.1498 on every $100 dollars invested by stockholders. Stryker's management efficiency ratios could be used to measure how well Stryker manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jochen Schmitz | Siemens Healthineers AG | 57 | |
| Scott Leinenweber | Abbott Laboratories | 51 | |
| Joseph Hogan | Align Technology | 66 | |
| Michel DVM | Siemens Healthineers AG | 62 | |
| Stuart Hockridge | Align Technology | 51 | |
| Daniel Brennan | Boston Scientific | 57 | |
| Ivan Fong | Medtronic PLC | 62 | |
| Joseph Fitzgerald | Boston Scientific | 59 | |
| Susan Lisa | Boston Scientific | 54 | |
| John Morici | Align Technology | 56 | |
| Jodi Eddy | Boston Scientific | 50 | |
| John Sorenson | Boston Scientific | 55 | |
| Darleen Caron | Siemens Healthineers AG | 59 | |
| Andrea Wainer | Abbott Laboratories | 53 | |
| Scott Ullem | Edwards Lifesciences | 56 | |
| Jonathan Monson | Boston Scientific | N/A | |
| Michael Mussallem | Edwards Lifesciences | 70 | |
| Zelko Relic | Align Technology | 58 | |
| Julie Coletti | Align Technology | 54 | |
| Shirley Stacy | Align Technology | N/A | |
| Andre Hartung | Siemens Healthineers AG | N/A | |
Management Performance
| Return On Equity | 0.15 | |||
| Return On Asset | 0.0618 |
Stryker Leadership Team
Elected by the shareholders, the Stryker's board of directors comprises two types of representatives: Stryker inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stryker. The board's role is to monitor Stryker's management team and ensure that shareholders' interests are well served. Stryker's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stryker's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Cohen, CTO Replacement | ||
| Alan Douville, Chief VP | ||
| Kevin Lobo, President CEO, Director | ||
| Glenn Boehnlein, CFO, Vice President | ||
| Jason Beach, VP Relations | ||
| Spencer Stiles, Group Spine | ||
| Viju Menon, Group President - Global Quality and Business Operations | ||
| Andrew Pierce, Group Neurotechnology | ||
| William Berry, Principal Accounting Officer, Vice President Corporate Controller | ||
| Timothy Scannell, Group President - MedSurg and Neurotechnology |
Stryker Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Stryker a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | |||
| Return On Asset | 0.0618 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 101.82 B | |||
| Shares Outstanding | 378.83 M | |||
| Shares Owned By Insiders | 1.79 % | |||
| Shares Owned By Institutions | 80.48 % | |||
| Price To Earning | 20.44 X | |||
| Price To Book | 5.77 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Stryker Stock
When determining whether Stryker is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stryker Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stryker Stock. Highlighted below are key reports to facilitate an investment decision about Stryker Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stryker. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Stryker Stock please use our How to Invest in Stryker guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..